At the current vaccination pace it will take over a decade for South Africa to reach herd immunity, with many lives lost along the way.
Articles on COVID-19 vaccine rollout
Displaying 41 - 60 of 87 articles
There are tangible things we can do now to help people understand the benefits and possible risks of COVID-19 vaccination.
Although most border workers are now vaccinated, regular testing remains essential to guard against the risk of a major outbreak in the community.
The Morrison government’s decision to drop vaccination targets goes against decades of research and evidence on the importance of goal-setting.
Both the AstraZeneca and Johnson & Johnson vaccines are now being investigated for links to rare blood disorders.
A vaccine expert breaks down everything you need to know about the Novavax vaccine.
The challenge now is to address the understandable concerns and prevent them from contaminating the broader public dialogue on COVID-19 vaccination.
We’ll need mass vaccination hubs and expanded GP vaccination clinics to deliver jabs to millions of Australians.
This shift in focus away from AstraZeneca to the Pfizer vaccine has serious impacts on the timing of the rollout and public confidence in the AstraZeneca vaccine.
Our well-meaning efforts to use images to help demystify the vaccination process or share our pride in getting a COVID vaccine can backfire.
All vaccines and medications come with risks. But the risks of delaying vaccination are far higher.
We need to stop relying on small GP clinics and urgently move towards using mass vaccination hubs like stadiums, schools and parks.
These mistakes have been mainly caused by our leaders giving priority to a good political story over good policy.
The anticipated arrival of two new vaccines can boost the morale of those worried about the wait for their dose.
At first glance, Australia looks to be tracking poorly compared to the rest of the world. However, context is really important here.
Exports of the vaccine continue to be a point of contention between the EU and UK, while newly released US trial results are quickly amended.
Pausing COVID-19 vaccine rollouts can backfire. There are better ways to manage safety issues while they’re being investigated.
This group has long suffered much higher death rates than the general population due to a poor standard of basic healthcare.
From today, around 1,000 clinics around the country can begin vaccinating eligible Australians.
The European Medicines Agency has said the Oxford/AstraZeneca vaccine is not associated with an increased overall risk of developing blood clots.
Top contributors
-
General Practitioner, PhD Candidate, Bond University
-
Honorary Enterprise Professor, School of Population and Global Health, and Department of General Practice and Primary Care, The University of Melbourne
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Professor of Epidemiology Healthcare Infection and Infectious Diseases Control, UNSW
-
Professor, The Children's Hospital at Westmead Clinical School and Sydney Infectious Diseases Institute, University of Sydney
-
Associate Professor, Epidemiology, Deakin University
-
Adjunct Associate Professor, Menzies Centre for Health Policy and Economics, University of Sydney
-
Chair in Epidemiology, Deakin University
-
Professor of Paediatrics and vaccinologist, Royal Childrens Hospital, University of Melbourne and Murdoch Childrens Research Institute (MCRI); Associate Dean International, University of Melbourne, Murdoch Children's Research Institute
-
Research Fellow in Applied Moral Philosophy, University of Oxford
-
Consultant Neonatologist and Professor of Ethics, University of Oxford
-
Professor of Global Biosecurity, NHMRC L3 Research Fellow, Head, Biosecurity Program, Kirby Institute, UNSW
-
Adjunct Professor: Department Internal Medicine, University of Pretoria
-
Research Fellow, Vaccine Uptake Group, Murdoch Children's Research Institute
-
Senior Associate, Grattan Institute